pbpk modeling to predict pharmacokinetics in hepatic impairment
Published 10 months ago • 598 plays • Length 50:49Download video MP4
Download video MP3
Similar videos
-
18:14
using pop pk modeling to optimize dosing in patients with organ impairment
-
55:39
a best practice framework for applying pbpk modeling to pediatric drug development
-
59:49
pbpk modeling approaches to assess risks associated with bioequivalence in drug development
-
40:57
precision dosing using pbpk modeling
-
59:17
strategic application of pbpk models for predicting ddis & the effects of smoking & organ impairment
-
49:40
pbpk modeling and simulation: bridging the “bottom up” and “top-down” approaches
-
20:08
1 introduction to pbpk modeling
-
55:43
pbpk modelling to predict drug-biologic interactions with cytokine modulators
-
49:17
pml school: metabolite kinetics
-
47:14
pml school: minimal physiologically-based pharmacokinetic model for monoclonal antibodies (mabs)
-
1:00:40
what's new in pbpk & the simcyp simulator
-
58:30
predicting drug exposure during pregnancy using pbpk models
-
50:40
application of pbpk modeling in predicting p-glycoprotein-mediated drug-drug interactions
-
57:29
predicting drug pharmacokinetics in pregnancy, fetal, and lactation using pbpk
-
39:27
the physiological basis of comparative pharmacokinetics
-
1:52
pbpk modeling supports approval of breakthrough cancer drug
-
1:01:14
pbpk modeling & simulation to support asciminib nda submission and inform drug product label
-
1:01:26
iq wg evaluation of pbpk models for organ-impaired populations
-
59:23
first-in-human (fih) faster: the power of physiologically based pharmacokinetic (pbpk) modeling
-
1:05:52
application of physiologically-based pharmacokinetics (pbpk) to personalized dosing
-
1:06:27
the importance of pbpk model validation and reproducibility in obstetric pharmacology
-
36:08
pbpk modeling of antibody-drug conjugates – concept and application